IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 197 filers reported holding IMPAX LABORATORIES INC in Q2 2015. The put-call ratio across all filers is 0.49 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $4,000 | +33.3% | 203 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $3,000 | -25.0% | 203 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $4,000 | +33.3% | 203 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $3,000 | +50.0% | 203 | +22.3% | 0.00% | 0.0% |
| Q4 2016 | $2,000 | -66.7% | 166 | -33.3% | 0.00% | -66.7% |
| Q3 2016 | $6,000 | 0.0% | 249 | +20.9% | 0.00% | 0.0% |
| Q2 2016 | $6,000 | +20.0% | 206 | +19.8% | 0.00% | 0.0% |
| Q1 2016 | $5,000 | -28.6% | 172 | 0.0% | 0.00% | -25.0% |
| Q4 2015 | $7,000 | +16.7% | 172 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $6,000 | -25.0% | 172 | 0.0% | 0.00% | -20.0% |
| Q2 2015 | $8,000 | 0.0% | 172 | -3.9% | 0.01% | 0.0% |
| Q1 2015 | $8,000 | +60.0% | 179 | +4.1% | 0.01% | +66.7% |
| Q4 2014 | $5,000 | 0.0% | 172 | -15.3% | 0.00% | -25.0% |
| Q3 2014 | $5,000 | 0.0% | 203 | +11.5% | 0.00% | +33.3% |
| Q2 2014 | $5,000 | 0.0% | 182 | 0.0% | 0.00% | -25.0% |
| Q1 2014 | $5,000 | – | 182 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aravt Global | 2,670,000 | $125,143,000 | 9.40% |
| Krensavage Asset Management, LLC | 410,944 | $19,261,000 | 8.77% |
| BANBURY PARTNERS LLC | 292,660 | $13,717,000 | 8.70% |
| Slate Path Capital LP | 1,935,000 | $90,693,000 | 5.72% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 285,000 | $13,358,000 | 4.69% |
| Orbimed Advisors | 6,678,000 | $312,998,000 | 2.67% |
| Pennant Capital Management, LLC | 2,025,000 | $94,912,000 | 1.78% |
| Iguana Healthcare Management, LLC | 75,000 | $3,515,000 | 1.48% |
| Leonard Capital Management, Inc. | 89,235 | $4,182,000 | 1.44% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $11,718,000 | 1.23% |